

# Theoretical Studies on the Mechanism of Conversion of Androgens to Estrogens by Aromatase<sup>†</sup>

Kenneth R. Korzekwa,\* William F. Trager,<sup>‡</sup> Soozy J. Smith,<sup>§</sup> Yoichi Osawa,<sup>§</sup> and James R. Gillette<sup>§</sup>

Laboratory of Chemical Pharmacology, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892, and Department of Medicinal Chemistry, University of Washington, Seattle, Washington 98195

Received August 17, 1990; Revised Manuscript Received March 28, 1991

**ABSTRACT:** Semiempirical molecular orbital calculations (AM1) were used to model several possible reaction mechanisms for the third oxidation of the aromatase-catalyzed conversion of androgens to estrogens. The reaction mechanisms considered are based on the assumption that the third oxidation is initiated by 1 $\beta$ -hydrogen atom abstraction. Homolytic cleavage of the C<sub>10</sub>-C<sub>19</sub> bond was modeled for both the 3-keto and 2-en-3-ol forms of the androgen 1-radicals. The addition of a protein nucleophile to the 19-oxo intermediate was also considered, and -OCH<sub>3</sub>, -SCH<sub>3</sub>, and -NHCH<sub>3</sub> were used to represent the Ser, Cys, and Lys adducts. The transition states were estimated and optimized from the reaction coordinates obtained by constraining and increasing the C<sub>10</sub>-C<sub>19</sub> bond lengths. The enthalpies of activation range from 14 to 21 kcal and are ~2 kcal lower for cleavage of the enol form. Given the tendency for AM1 to overestimate activation energies, all reactions may be energetically accessible. Other reactions modeled include a homolytic cleavage reaction from a thioether radical cation and the direct additions of oxygen radical compounds to the carbonyl of the 1-radical-2-en-3-ol-19-oxo androgen. A mechanism is proposed in which the 19-oxo intermediate is subject to initial nucleophilic attack by the protein. Since rotation of the 19-carbonyl can bring the oxygen within 2.1 Å of the 2 $\beta$ -hydrogen, the formation of a tetrahedral intermediate can occur with concomitant removal of the 2 $\beta$ -proton. Enolization activates the C<sub>1</sub>-position for hydrogen atom abstraction, since the resulting radical is resonance stabilized. Homolytic cleavage of this radical is followed by recombination of the C<sub>19</sub>-radical with the hydroxy radical equivalent. The geometry of the carbonyl oxygen in the androgens is between that for the 1-radicals and estrogen, suggesting that some transition-state stabilization for the homolytic cleavage reaction may occur.

The cytochrome P-450 enzymes are a superfamily of monooxygenases capable of oxidizing a wide variety of both exogenous and endogenous compounds (Ortiz de Montellano, 1987; Guengerich, 1987). Whereas many of the isozymes have broad substrate specificity and have apparently evolved for the metabolism of foreign compounds, some of the isozymes are very specific for certain endogenous substrates. One of the most remarkable cytochrome P-450s is aromatase, the enzyme responsible for the conversion of androgens to estrogens. This enzyme has received considerable attention over the last 30 years (Ryan, 1959; Engle, 1973), with much of the effort directed at the development of inhibitors to be used in the treatment of estrogen-dependent breast cancer (Brodie et al., 1982; Santen, 1982; Siteri, 1982; Van Wauwe & Janssen, 1989).

The general reaction sequence for aromatase is shown in Scheme I. It has been shown that three molecules of molecular oxygen and six reducing equivalents from NADPH are consumed during estrogen formation (Thompson & Siiteri, 1974). The androgen is first oxidized to the C<sub>19</sub>-hydroxy androgen and then oxidized to the C<sub>19</sub>-gem-diol or its dehydrated form, the C<sub>19</sub>-aldehyde. The mechanism of the third oxidation is still undefined, even though considerable information regarding the reaction has been established over the years. For example, it is known that the specific removal of

both the 1 $\beta$ - and 2 $\beta$ -hydrogens (Townsend & Brodie, 1968; Brodie et al., 1959; Fishman et al., 1969; Osawa & Spaeth, 1971) and the incorporation of an atom from molecular oxygen into formate (Akhtar et al., 1981; Stevenson et al., 1985), the final form of the C<sub>19</sub>-methyl group, are obligatory steps in the reaction sequence. Most of the proposed detailed mechanisms for this step have been precluded by these requirements. The requirements are still consistent with a mechanism that has received attention in recent years that postulates the addition of the ferric peroxy anion from aromatase to the C<sub>19</sub>-aldehyde. The resulting alkyl peroxy intermediate then decomposes either in a direct manner (Cole & Robinson, 1988) or via the 10-hydroxy intermediate (Watanabe & Ishimura, 1989a,b) to give the estrogen as the final product. In support of this mechanism is the demonstration that the protected enol of the 19-oxo androgen is converted to the estrogen upon treatment with hydrogen peroxide (Cole & Robinson, 1988). Although the involvement of a 10-hydroxy intermediate has been shown to be unlikely (Covey et al., 1984; Caspi et al., 1989), a peroxide-mediated mechanism is consistent with the available data. However, some aspects of this mechanism remain troubling. For example, a wealth of evidence suggests that the catalytically competent species generated by cytochrome P-450 is a ferric-bound oxygen atom (oxene). Indeed, this species is believed to mediate the first two oxidative steps in the aromatase reaction. If this is true, then the requirement of a totally different form of activated oxygen for the third step seems puzzling. So far as we are aware, documentation of a cytochrome P-450 catalyzed addition of peroxy anion to a carbonyl group has not appeared in the literature. This question then arises: Is aromatase unique, or are other mechanisms possible that involve an oxene as the reactive oxygen species and that are equally or more consistent with


<sup>†</sup>Supported in part by the National Institutes of Health (Grant GM 36922) and in part by a PRAT Fellowship (K.R.K.) from the National Institutes of General Medical Sciences.

\* To whom correspondence should be addressed at Laboratory of Molecular Carcinogenesis, National Cancer Institute, National Institutes of Health, Building 37, Room 3E24, Bethesda, MD 20892.


<sup>‡</sup>University of Washington.

<sup>§</sup>National Heart, Lung, and Blood Institute.

Scheme I



Scheme II



the available experimental data?

Covey and co-workers (Beusen et al., 1987; Covey et al., 1987) have discussed a general oxene mechanism in which  $1\beta$ -hydrogen abstraction precedes homolytic cleavage of the  $C_{10}$ - $C_{19}$  bond. Two observations provide support for a modified version of this mechanism. (1) Consideration of molecular models indicated that the carbonyl oxygen of the  $C_{19}$ -aldehyde can approach the  $2\beta$ -hydrogen to within 2.1 Å. Promotion of the removal of the  $2\beta$ -hydrogen by the  $C_{19}$ -carbonyl would account for the experimentally known stereospecific loss of this hydrogen atom as well as the catalyzing enolization of the 3-keto group, which is mandatory for product formation. (2) Mechanistic studies on the cytochrome P-450 catalyzed desaturation reactions (Scheme II) suggest that the hydroxy radical equivalent formed by hydrogen atom abstraction is not always committed to recombination with the radical (Nagata et al., 1986; Rettie et al., 1987, 1988; Korzekwa et al., 1990a). With regard to the first observation, the


$C_{19}$ -carbonyl could efficiently effect enolization by undergoing an initial attack by a nucleophile from an appropriate amino acid residue of the apoprotein. Presumably, this amino acid would be part of the construct of the active site of the enzyme and would be critically oriented for catalysis. Such an attack would generate an oxygen anion whose carbon-oxygen bond would be elongated relative to the carbon-oxygen double bond, bringing the negative charge in even closer proximity to the  $2\beta$ -hydrogen and thereby catalyzing enolization. After enolization has occurred, the energy of activation for removal of the  $1\beta$ -hydrogen by cytochrome P-450 to generate a carbon-based radical at  $C_1$  would be lowered by resonance stabilization. This analysis together with the second observation led us to speculate that abstraction of the  $1\beta$ -hydrogen atom might precede  $C_{10}$ - $C_{19}$  bond cleavage and occur with minimal recombination to the hydroxy radical. Osawa et al. (1987a,b) found that substantial amounts of  $1\beta$ - and  $2\beta$ -hydroxy androgens are formed by aromatase when the  $C_{19}$ -methyl group is completely tritiated, suggesting that both sites ( $1\beta$  and  $2\beta$ ) are accessible to the active oxygen and susceptible to attack when the conditions are appropriate. The next step in the postulated mechanism would be the aromatization of the A-ring of the steroid by homolytic cleavage of the  $C_{10}$ - $C_{19}$  bond. This would then be followed by addition of the hydroxy radical equivalent to the  $C_{19}$ -radical to generate an orthoformate-bound enzyme and estrogen (Scheme III).

In order to evaluate possible oxene-based mechanisms for the third oxidative step in the aromatase reaction, semiempirical theoretical calculations (AM1) were used to model various hypothetical reaction pathways. The results of these calculations are the subject of this paper.

## METHODS


The semiempirical quantum chemical calculations were performed on a Microvax II with use of the AM1 (Dewar et

Scheme III






Scheme V



Scheme VI



and products are given in Figure 2. The enthalpies of activation ranged from 14.0 kcal/mol for  $R = -NHCH_3$  to 20.0 kcal/mol for  $R = -OCH_3$ . For  $R = -OH$  and  $R = -SCH_3$ , the enthalpies of activation for homolytic cleavage of the enol forms of the radicals are about 2 kcal/mol lower in energy than those for the corresponding keto forms. Also, similar differences in activation enthalpies for these two substitutions within each reaction suggest that stabilization characteristics for the two reactions are similar.

#### Homolytic Cleavage of Sulfur Radical Cation Analogues.

In addition, we have considered the possibility that after cysteine adduct formation an electron is abstracted from the sulfur atom after abstraction of the 1-hydrogen atom to aid in homolytic cleavage (Scheme V). Such electron abstraction reactions have been proposed as the first step in other cytochrome P-450 mediated oxidations (Ortiz de Montellano, 1989). Since the hydroxyl radical equivalent formed by hydrogen atom abstraction is apparently capable of abstracting an additional hydrogen atom (Korzekwa et al., 1990a), the abstraction of an electron to form a hydroxide intermediate seems plausible. In order to model this reaction, a biradical cation species is required, with one unpaired electron in the A-ring of the steroid and one unpaired electron on the sulfur. Since the lowest energy cation for the thiomethyl adduct of the 2-en-3-ol form will have the cation in the A-ring (closed-shell cation), it was necessary to generate the required electronic configuration (biradical cation) by abstracting an electron from the sulfur atom with a proton. This was accomplished by first protonating the sulfur atom and then generating a reaction coordinate where the hydrogen-sulfur distance is slowly increased to 30 Å, beginning the SCF calculation at each point with the density matrix from the previous point. Unfortunately, while the biradical cation could be generated in this manner, when the  $C_{10}$ - $C_{19}$  bond length was increased to induce homolytic cleavage, the thiomethyl cation rotated above and formed a bond to the  $C_1$ -position. In order to prevent this interaction, the thiomethyl position was constrained by attaching the methyl carbon to the  $C_8\beta$ -




FIGURE 3: Activation enthalpies for  $C_{10}$ - $C_{19}$  cleavage of the constrained radical and biradical cations.

position of the B-ring (Figure 3). It was then necessary to compare a homolytic cleavage reaction with the constrained structure to the same reaction for the unconstrained structure. Cleavage of the  $C_{10}$ - $C_{19}$  bond for the 1-radical-2-en-3-ol thiomethylene compound gave an enthalpy of activation of 17.4 kcal/mol, 1.4 kcal lower than that for the unconstrained thiomethyl analogue. This lower activation enthalpy is due to conformational strain associated with attaching the thiomethyl group to the  $C_8$ -position, some of which is relieved in the transition state. A proton was then used to abstract an electron from the sulfur giving the constrained biradical cation. Homolytic cleavage of this compound had an activation energy of 17.0 kcal/mol, 0.4 kcal/mol lower than that for the non-cation.

**Addition of Various Oxygen Radicals to the 1-Radical-2-en-3-ol-19-oxo Steroid Analogue.** In a manner analogous to that proposed for cytochrome P-450 mediated desaturation reactions, a simple reaction mechanism involving the addition of various oxygen-radical species to the carbonyl carbon of the 1-radical-2-en-3-ol-19-oxo steroid analogue was modeled

(Scheme VI). Addition of a hydroxy radical to the 19-carbonyl on the UHF surface resulted in a smooth reaction coordinate from reactants to products (formate and the estrogen analogue). A transition state for the reaction was characterized and had an activation energy of 9.6 kcal/mol. While this activation energy is quite low, particularly for AM1/MNDO calculations, the tremendous reactivity of the hydroxy radical (and the associated exothermicity of the reaction) suggests that this radical is not appropriate to model cytochrome P-450 mediated reactions (Korzekwa et al., 1990b). However, when more stabilized radicals were used, in particular the phenoxy and ethyleneoxy radicals, a "chemical hysteresis" resulted (Friedrich et al., 1988), with a sudden change in electronic structure occurring before a transition state was reached. Although the addition of the phenoxy radical proceeded smoothly to the point where the reaction coordinate gradient began to decrease, the transfer of the radical from the aromatic ring to the carbonyl oxygen resulted in a sudden decrease in energy. Further addition resulted in a tetrahedral intermediate, which had a small barrier for cleavage of the C<sub>10</sub>-C<sub>19</sub> bond to give products. Beginning with the tetrahedral intermediate and increasing the C<sub>19</sub>-O bond length resulted in similar behavior, with the reaction proceeding with the radical on the carbonyl oxygen and then changing to the electronic structure with the radical in the aromatic ring. However, observation of the energy relative to the reaction gradients suggests that the activation energies associated with the transition states on both potential energy surfaces exceed 30 kcal/mol.

## DISCUSSION

The intent of this study was to explore the energetics for mechanisms leading to the aromatization of the 19-oxo androgens that rely on the oxene species of cytochrome P-450 and that are consistent with presently available experimental data. The general mechanisms that have been considered have been discussed previously by Covey et al. (1987) and involve abstraction of the 1 $\beta$ -hydrogen atom by the oxene prior to cleavage of the C<sub>10</sub>-C<sub>19</sub> bond. While this abstraction can occur from either the 3-keto or 2-en-3-ol androgens, abstraction from the enol form offers two advantages over abstraction from the keto form. First, the 1-radical would be conjugated to the adjacent 2,4-dien-3-one, lowering the activation energy for the reaction. The AM1 results in Figure 1 show that the conjugated radical is 19 kcal/mol more stable than the unconjugated radical. A recent study using a model oxygen radical to predict the tendency for hydrogens to be abstracted by cytochrome P-450 (Korzekwa et al., 1990b) suggests that the activation energy should be lowered by 30%.<sup>1</sup> In addition to activating the 1-position, the stability of the radical would also increase the activation energy for recombination, allowing alternative reactions to take place.

In the mechanism proposed in Scheme III, the C<sub>19</sub>-carbonyl is subject to initial attack by a nucleophilic residue provided by the apoprotein with concomitant removal of the 2 $\beta$ -proton to generate the enol. Since the hypothetical nucleophilic amino acid is unknown, calculations were performed on various likely

possibilities. Thus, the C<sub>19</sub>-carbonyl addition products containing -OH, -OCH<sub>3</sub>, -NHCH<sub>3</sub>, and -SCH<sub>3</sub> were selected to mimic the addition of H<sub>2</sub>O, serine, lysine, and cysteine. In addition, the pathway involving homolytic cleavage of the C<sub>10</sub>-C<sub>19</sub> bond from the 3-keto-1-radical to the C<sub>19</sub>-gem-diol has been modeled to provide an energy estimate for the mechanism proposed by Beusen et al. (1987). This reaction was also modeled with the -SCH<sub>3</sub> addition product in order to compare the two reactions.

For homolytic cleavage reactions from the 2-enol forms of the 1-radicals, the enthalpies of activation for the serine and cysteine models were found to be 20.0 and 18.8 kcal/mol, respectively (Figure 2). Two different conformations with respect to the nitrogen lone pair of the enol methylamine addition product gave activation enthalpies of 16.6 kcal/mol for the (*S*)-amine conformation and 14.0 kcal/mol for the (*R*)-amine conformation. The lower value of the (*R*)-conformation appears to be due to steric interactions of the amine proton with the B-ring in the ground state. The starting geometries used in all calculations were chosen to be the local minima corresponding to attack of the protein nucleophile from the C<sub>11</sub>-direction.

The range of energies found (14.0–20.0 kcal/mol) is not sufficient to preclude the involvement of any one of the amino acids considered as the nucleophilic species. Moreover, the tendency for MNDO (AM1) to overestimate activation energies suggests that the involvement of an amino acid nucleophile in the reaction sequence is energetically feasible. Thus, given the favorable energetics for the formation of the C<sub>1</sub>-radical after enolization and the possibility of catalyzing enolization by nucleophilic attack, invoking the formation of the enolic 1-radical prior to C<sub>10</sub>-C<sub>19</sub> bond cleavage appears justified. Nevertheless, the relative energetics for C<sub>10</sub>-C<sub>19</sub> bond cleavage without prior enolization, that is, from the ketone, should be considered and compared to the energetics for C<sub>10</sub>-C<sub>19</sub> bond cleavage after enolization.

Homolytic cleavage of the C<sub>10</sub>-C<sub>19</sub> bond after 1 $\beta$ -hydrogen abstraction was first proposed by Beusen et al. (1987). In this mechanism, we propose that abstraction and cleavage occurs from the 1-radical-3-keto-19-gem-diol intermediate (Scheme IV). The hydroxy radical then recombines with the gem-diol radical to form orthoformate. Enolization occurs when orthoformate deprotonates the 2 $\beta$ -position during dehydration to give the estrogen and formate. Provided that the oxygen atom from the second oxidation abstracts the 2-proton and is lost as water, this mechanism accounts for loss of the 1 $\beta$ - and 2 $\beta$ -protons as well as the incorporation of the first and third oxygen atoms into formate.

Homolytic cleavage reactions for the gem-diol and the methanethiol addition product were modeled for both the ketone and enol form. For both compounds, the enthalpies of activation for the enol forms were  $\sim$ 2 kcal/mol lower than for the keto forms (Figure 2).

Thus, the major difference between the protein adduct mechanism proposed here and that of Beusen et al. (1987) resides clearly not in the energetics for C<sub>10</sub>-C<sub>19</sub> bond cleavage from the C<sub>1</sub>-radicals but instead in the difference in energy required for C<sub>1</sub>-radical formation.

Two additional mechanisms that were considered include homolytic cleavage of the C<sub>10</sub>-C<sub>19</sub> bond from the thio radical cation addition product and the direct addition of hydroxy radical to the 19-carbonyl group. Although the transition state for cleavage of the C<sub>10</sub>-C<sub>19</sub> bond from the radical cation was slightly lower (0.4 kcal/mol) than that for the corresponding thio species, such a small difference in energy does not justify

<sup>1</sup> The activation energy for this reaction was predicted from calculated radical stabilities and ionization potentials of the 3-keto and 2-enol AB-ring analogues as in Korzekwa et al. (1990b). The calculated activation energies are given in Figure 5. Since the computational methods tend to overestimate activation energies, the results should be considered qualitative. Since the predictive method was normalized by transition-state symmetry, discussions of fractional changes in activation energies may be more valid.






FIGURE 4: Overlay of geometries for 2-enol and 3-keto forms of the substrates, intermediates, transition states, and products.

invoking an additional electron abstraction step.

The gas-phase calculation for the addition of a hydroxy radical to the 1-radical-2-en-3-ol (Scheme VI) proceeds smoothly with concomitant homolytic cleavage to give the aromatic product and formate with  $\Delta H = 9.6$  kcal/mol. The activation energy for the addition of a hydroxy radical is probably much lower than would be calculated for a heme-stabilized hydroxy radical. Although transition states could not be obtained for addition of the more stable phenoxy and ethyleneoxy radicals, the estimated activation energies were  $> 30$  kcal/mol. However, although the activation energy for direct addition of a more stabilized hydroxy radical species (as is expected to be delivered by the enzyme) would be higher than that for the hydroxy radical, the direct-addition mechanism remains a possibility, since the transition-state symmetry for the recombination reaction and, therefore, the characteristics of the hydroxy radical equivalent remain unknown.

An additional advantage for homolytic cleavage after initial  $1\beta$ -hydrogen abstraction can be seen if the geometries of the compounds are considered. Table I gives the  $C_9-C_8-C_7-C_x$  dihedral angles for the full steroids modeled and a representative group of partial steroids. The similarities between the complete steroids and their AB-ring analogues suggest that alignment of the  $C_7$ ,  $C_8$ , and  $C_9$  atoms will provide a reasonable model for comparing potential protein steroid interactions. Both the enol and ketone form of the 1-radical have geometries with the A-ring bent below the plane of the steroid (similar

Table I: Dihedral Angles ( $C_9-C_8-C_7-C_x$ ) for Selected Optimized Geometries and Transition States

compound	$\tau$					
	$x = 6$	$x = 5$	$x = 4$	$x = 3$	$x = 2$	$x = 1$
testosterone (T)	301.6	328.1	333.9	338.8	337.7	344.7
T A-analogue (TAB)	303.3	329.1	334.7	339.6	339.1	346.3
T 2-enol	301.0	327.4	331.9	337.0	341.2	345.0
TAB 2-enol	301.2	327.7	331.9	337.1	341.6	345.8
T 2-enol-1-radical	303.2	330.3	339.2	345.3	346.6	343.1
TAB 2-enol-1-radical	305.0	331.9	339.9	346.1	348.3	345.3
TAB 1-radical	304.4	330.9	338.2	343.8	344.7	345.3
estrogen AB-analogue	298.3	321.5	319.1	325.3	339.1	346.3
TS 2-enol-1-radical	301.2	327.4	329.5	336.4	342.6	345.0
TS 3-keto-1-radical	300.3	326.6	328.5	335.3	340.7	344.5

to the geometry reported for androsta-1,4-dien-3-one steroids; Duax, 1971) while the product estrogen has an A-ring that is bent up above the steroid (see Figure 4, top and bottom). The large change in the geometry of the product has been postulated to cause a fast rate of product release (Osawa, 1973). Both the androgens and the transition states for homolytic cleavage have A-ring geometries that are between reactants (1-radicals) and products (estrogens). If polar interactions between the 3-carbonyl (or enol) and the enzyme are involved in binding, the transition state for the enol may be bound more tightly than that for the ketone, since the position of the oxygen atom is closer to that for the androgen substrate. The  $K_m$  for androstenedione is 10 nM, which corresponds to a large amount of binding energy (11.3 kcal/mol, provided  $K_m$  approximates  $K_b$ ). This suggests that substantial transition-state stabilization may be involved in the homolytic cleavage reaction. These binding influences will be limited to the cleavage reaction, since enolization (Table I) and substitution at  $C_{19}$  do not result in large changes in geometry.

The mechanisms of suicide inhibitors for aromatase can also be used to evaluate the reaction pathways proposed above. The presence of a nucleophile in the active site of aromatase is strongly suggested by time-dependent irreversible inactivation caused by the 19,19-difluoroandrost-4-ene-3,17-dione (Marcotte & Robinson, 1982). This compound is presumably metabolized to the acylfluoride that covalently binds to an active site nucleophile. It has also been shown that 6 $\beta$ -bromoandrostenedione but not 6 $\alpha$ -bromoandrostenedione is a mechanism-based irreversible inhibitor of aromatase (Osawa et al., 1987c). From the enol form of the 1-radical, homolytic cleavage of the  $C_6$ -Br bond could compete with  $C_{10}$ - $C_{19}$  bond cleavage, giving the 1,3,5-trien-3-ol, a bromine radical, and a hydroxy radical equivalent. Addition of the hydroxy radical to the unsaturated steroid would result in a carbon-based radical. Carbon-based radicals have been known to cause both




FIGURE 5: Overall calculated thermodynamic properties (AM1) for potential pathway for the aromatization of androgens. <sup>a</sup>Calculated as in Korzekwa et al. (1990b).

heme modification and cross-linking of the heme to the apo-protein (Osawa et al., 1990, 1991). Since the 6 $\beta$ -position is axial, this reaction is possible for the 6 $\beta$ -bromo analogue but not for the 6 $\alpha$ -bromo analogue. If this mechanism is correct, it suggests that C<sub>10</sub>–C<sub>19</sub> bond cleavage occurs from the 2-en-3-ol form of the 1-radical.

A general scheme showing the relative thermodynamic properties of both the 3-keto and 2-en-3-ol androgens is shown in Figure 5. On the basis of this information and the above discussion, we favor the following mechanism. The active oxygenating species is situated closest to the C<sub>19</sub>-methyl group and above the C<sub>1</sub>- and C<sub>2</sub>-carbon atoms (Kellis et al., 1987; Osawa et al., 1987a,b). The substrate remains in the keto form for the first two oxidations, which occur at the C<sub>19</sub>-methyl group to give the 19-oxo intermediate. Addition of an active site nucleophile to the aldehyde catalyzes the enolization of the 2-position, activating the C<sub>1</sub>-position. Abstraction of the 1 $\beta$ -hydrogen atom gives a radical intermediate with a decreased binding energy due to large geometry changes in the A-ring of the steroid. The binding energy is then regained at the transition state, lowering the energy of activation. The hydroxy radical equivalent recombines with the substituted methyl radical to give an orthoformate analogue from which formate is released. The above mechanism accounts for the selective loss of the 1 $\beta$ - and 2 $\beta$ -hydrogen atoms and the incorporation of the third atom from molecular oxygen into formate.

The position of the active oxygen relative to the substrate is supported both by the small amount (~1% each) of 1 $\beta$ - and 2 $\beta$ -hydroxylation (Osawa et al., 1987a,b)] and by the stereoselective binding of type II inhibitors (Kellis et al., 1987). The advantage of an aldehyde-induced enolization reaction is that the 1-position will be deactivated until the third oxidation. If the ratio of 19-hydroxylation to 1 $\beta$ - and 2 $\beta$ -hydroxylations is due to substrate orientation (binding interactions), this would correspond to an energy difference of ~3 kcal/mol. The predicted decrease in activation energy for 1 $\beta$ -hydrogen atom abstraction due to conjugation with the dienol is 7 kcal/mol.<sup>1</sup> While this prediction should be considered qualitative, even 1 kcal/mol would result in a substantial amount of 1 $\beta$ -hydroxy androgen. Although it is possible that the 1% 1 $\beta$ -hydroxylation is due to a small amount of enol in equilibrium with the keto form, it would require that the 1 $\beta$  and 2 $\beta$ -products be formed from different species, since 2 $\beta$ -hydroxylation cannot occur from the 2-enol. Osawa et al. (1987a,b) have shown that for [19-<sup>3</sup>H<sub>3</sub>]androstenedione both 1 $\beta$ - and 2 $\beta$ -hydroxylation are greatly increased. Therefore, both 1 $\beta$ - and 2 $\beta$ -hydroxylation reactions are in direct competition with 19-hydroxylation. In addition, although the calculated activation enthalpies for homolytic cleavage reactions are only 10% lower for the enol forms, the rate of radical recombination (which would be in competition with C<sub>10</sub>–C<sub>19</sub> cleavage) should be substantially faster for the isolated  $\sigma$ -radical of the 3-ketone than for the conjugated  $\pi$ -radical of the 2-enol. Finally, the calculated transition states for homolytic cleavage of both the ketones and enols have geometries similar that of to the initial androgen, suggesting that the substrate binding characteristics are also involved in transition-state stabilization.

## REFERENCES

- Akhtar, M., Calder, M. R., Corina, D. L., & Wright, J. N. (1981) *J. Chem. Soc., Chem. Commun.*, 129–130.
- Beusen, D. D., Carrell, H. L., & Covey, D. F. (1987) *Biochemistry* 26, 7833–7841.
- Brodie, A. M. H. (1982) *Cancer Res.* 42, 3312–3314.
- Brodie, H. J., Kripalani, K. J., & Possanza, G. (1969) *J. Am. Chem. Soc.* 91, 1241–1242.
- Cole, P. A., & Robinson, C. H. (1988) *J. Am. Chem. Soc.* 110, 1284–1285.
- Covey, D. F., Hood, W. F., Beusen, D. D., & Carrell, H. L. (1984) *Biochemistry* 23, 5398–5406.
- Covey, D. F., Carrell, H. L., & Beusen, D. D. (1987) *Steroids* 50, 363–374.
- Dewar, M. J. S., Zuebis, E. G., Healy, E. F., & Stewart, J. (1985) *J. Am. Chem. Soc.* 107, 3902–3909.
- Duax, W., Norton, D., Pokrywiewski, S., & Eger, C. (1971) *Steroids* 18, 525–544.
- Engle, L. L. (1973) in *Handbook of Physiology and Endocrinology, Part 1* (Greep, R., Astwood, S., & Geiger, B., Eds.) Vol. 2, pp 467–483, American Physiological Society, Washington, DC.
- Fishman, J., Guzik, H., & Dixon, D. (1969) *Biochemistry* 8, 4304–4309.
- Friedrich, B., Herman, Z., Zahradnik, R., & Havlas, Z. (1988) *Adv. Quantum Chem.* 19, 247–288.
- Guengerich, F. P. (1987) *Mammalian Cytochromes P-450, Vol. 1 and 2*, CRC Press, Boca Raton, FL.
- Kellis, J. T., Jr., Childers, W. E., Robinson, C. H., & Vickery, L. E. (1987) *J. Biol. Chem.* 262, 4421–4426.
- Korzekwa, K. R., Trager, W. F., Nagata, K., Parkinson, A., & Gillette, J. R. (1990a) *Drug Metab. Dispos.* 18, 974–979.
- Korzekwa, K. R., Jones, J. P., & Gillette, J. R. (1990b) *J. Am. Chem. Soc.* 112, 7042–7046.
- Marcotte, P. A., & Robinson, C. H. (1982) *Biochemistry* 21, 2773–2778.
- Nagata, K., Liberato, D. J., Gillette, J. R., & Sasame, H. A. (1986) *Drug Metab. Dispos.* 14, 559–565.
- Ortiz de Montellano, P. R. (1987) *Cytochrome P-450, Structure, Mechanism, and Biochemistry*, Plenum Press, New York.
- Ortiz de Montellano, P. R. (1989) *Trends Pharmacol. Sci.* 10, 354–359.
- Osawa, Y. (1973) in *Endocrinology, Proceedings of the 4th International Congress of Endocrinology* (Scow, R. O., Ed.) pp 814–819, Excerpta Medica, Amsterdam.
- Osawa, Y., & Spaeth, D. G. (1971) *Biochemistry* 10, 66–71.
- Osawa, Y., Higashitama, T., Fronckowiak, M., Yoshida, N., & Yarborough, C. (1987a) *J. Steroid Biochem.* 27, 781–789.
- Osawa, Y., Yoshida, N., Fronckowiak, M., & Kitawaki, J. (1987b) *Steroids* 50, 11–28.
- Osawa, Y., Osawa, Y., & Coon, M. J. (1987c) *Endocrinology* 121, 1010–1015.
- Osawa, Y., Martin, B. M., Griffin, P. R., Yates, J. R., Shabanowitz, J., Hunt, D. F., Murphy, A. C., Chen, L., Cotter, R. J., & Pohl, L. R. (1990) *J. Biol. Chem.* 265, 10340–10346.
- Osawa, Y., Highet, R. J., Bax, A., & Pohl, L. R. (1991) *J. Biol. Chem.* 266, 3208–3214.
- Rettie, A. W., Rettenmeier, A. W., Howald, W. N., & Baillie, T. A. (1987) *Science* 235, 890–893.
- Rettie, A. W., Boberg, M., Rettenmeier, A. W., & Baillie, T. A. (1988) *J. Biol. Chem.* 263, 13733–13738.
- Ryan, K. J. (1959) *J. Biol. Chem.* 234, 268–272.
- Santen, R. J. (1982) *Cancer Res.* 42, 3268.
- Siiteri, P. K. (1982) *Cancer Res.* 42, 3269–3273.
- Stevenson, D. E., Wright, J. N., & Akhtar, M. (1985) *J. Chem. Soc., Chem. Commun.* 1078–1080.
- Thompson, E. A., Jr., & Siiteri, P. K. (1974) *J. Biol. Chem.* 249, 5364–5372.

Townsley, J. D., & Brodie, H. J. (1968) *Biochemistry* 7, 33-40.  
 Van Wauwe, J. P., & Janssen, A. J. (1989) *J. Med. Chem.* 32, 2231-2239.

Watanabe, Y., & Ishimura, Y. (1989a) *J. Am. Chem. Soc.* 111, 410-411.  
 Watanabe, Y., & Ishimura, Y. (1989b) *J. Am. Chem. Soc.* 111, 8047-8049.

## Rotational Mobility of High-Affinity Epidermal Growth Factor Receptors on the Surface of Living A431 Cells<sup>†</sup>

Raphael Zidovetzki,<sup>\*,‡</sup> David A. Johnson,<sup>§</sup> Donna J. Arndt-Jovin,<sup>||</sup> and Thomas M. Jovin<sup>\*,||</sup>

*Department of Biology and Division of Biomedical Sciences, University of California, Riverside, California 92521, and  
 Abteilung Molekulare Biologie, Max-Planck-Institute für Biophysikalische Chemie, W-3400 Göttingen, FRG*

*Received January 9, 1991; Revised Manuscript Received March 16, 1991*

**ABSTRACT:** The rotational diffusion of epidermal growth factor (EGF) bound to its specific receptor on the surface of human carcinoma A431 cells was studied by means of time-resolved phosphorescence anisotropy measurements. The rotational mobility was measured on the total population of EGF receptors by using a saturating concentration of EGF conjugated with a phosphorescent label, erythrosin, or on the subpopulation of high-affinity EGF receptors by using a low concentration of labeled EGF. At 4 °C, the rotational correlation times for both the high-affinity and total (mostly low affinity) receptor populations were in the range of 60–100  $\mu$ s. Elevation of the temperature to 37 °C resulted in a lengthening of the rotational correlation time of the total receptor population to 200–300  $\mu$ s, confirming a previous study of receptor microaggregation. The high-affinity EGF receptors were completely immobilized at 37 °C (rotational correlation time >500  $\mu$ s). The data are consistent with a model involving association of the cytoskeleton with the high-affinity receptors at 37 °C, but not at 4 °C.

**E**pidermal growth factor (EGF)<sup>1</sup> is a 6045-Da polypeptide which binds to specific membrane receptors (EGFR) present as integral membrane proteins in a wide variety of cells (Carpenter & Cohen, 1979; Adamson & Rees, 1981). Binding initiates a number of biochemical processes including activation of intrinsic tyrosine kinase activity (Cohen et al., 1982; Burow et al., 1983), increased ion and metabolite transport, and stimulated proliferation of the target cells (Gospodarowicz et al., 1978; Carpenter & Cohen, 1979). EGFR is one of the most studied cell-surface receptors. Its primary amino acid sequence has been deduced by Ullrich et al. (1984), who also provided a tentative identification of an external hormone binding domain, a single membrane-spanning domain, and a cytoplasmic domain which exhibits the tyrosine kinase activity. EGFR is a member of a family of receptors with certain common features in their mechanism of action [see Gill et al. (1987), Carpenter (1987), Yarden and Ullrich (1988), and Schlessinger (1988) for reviews].

Two general mechanisms have been suggested to explain the transmembrane signal transduction by EGFR (Schlessinger, 1986; Basu et al., 1986): (1) EGF binding induces a conformational change of the receptor that propagates through the membrane by a single membrane-spanning domain of EGFR (intramolecular mechanism); (2) EGF binding induces a change in receptor-receptor interaction leading to activation of the cytoplasmic tyrosine kinase (intermolecular mechanism). Both mechanisms have experimental support (Basu et al., 1986; Koland & Cerione, 1988; Yarden & Schlessinger,

1987a,b; Boni-Schnetzler & Pilch, 1987).

The intermolecular mechanism was proposed to involve "microclustering" of EGFR as a necessary prerequisite for the biological response (Schlessinger et al., 1983). Indeed, EGF induces rapid formation of small receptor aggregates (not distinguishable by light microscope) immediately following binding to EGFR (Carpenter & Cohen, 1976; Zidovetzki et al., 1981). Receptor aggregation was recently shown to be linked to a modification of the tyrosine kinase activity of EGFR (Carraway et al., 1989). Formation of microclusters of EGFR upon EGF binding was also demonstrated on cell-free A431 cell membrane suspensions (Zidovetzki et al., 1986; Azevedo & Johnson, 1991). Moreover, EGF-induced dimerization of EGFR has been observed with detergent-solubilized preparations of EGFR (Boni-Schnetzler & Pilch, 1987; Yarden & Schlessinger, 1987a,b; Cochet et al., 1988).

A transition from a mobile to an aggregated state of a receptor takes place in other systems. For example, receptor immobilization was reported after binding of nerve growth factor to its cell-surface receptor (Levi et al., 1980). In the case of insulin, the biological effects of the hormone were mimicked by cross-linking the insulin receptor with specific anti-receptor antibodies [Kahn et al., 1978; Jacobs et al., 1978; see Gill et al. (1987) for a critique of the clustering hypothesis].

The change in mobility, however, does not have to involve receptor self-aggregation; association with other plasma membrane molecules or cytoskeleton would also result in reduced receptor mobility. In the latter case, complete immobilization of the receptors would be expected, which would

<sup>†</sup> This work was supported by Grant BC-590 from the American Cancer Society (to R.Z.).

<sup>‡</sup> Department of Biology, University of California.

<sup>§</sup> Division of Biomedical Sciences, University of California.

<sup>||</sup> Max-Planck-Institute für Biophysikalische Chemie.

<sup>1</sup> Abbreviations: EGF, epidermal growth factor; Er-EGF, EGF labeled with erythrosin 5'-isothiocyanate; [<sup>125</sup>I]EGF, EGF labeled with <sup>125</sup>I; EGFR, EGF receptor(s); HA-EGFR, high-affinity EGFR; LA-EGFR, low-affinity EGFR; PBS, phosphate-buffered saline.